News

Video

Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy

Author(s):

Laura Huppert, MDYara Abdou, MD

Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.

Related Videos
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
VK Gadi, MD, PhD
Ana Christina Garrido-Castro, MD
Julia Foldi, MD, PhD
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Kevin Kalinsky, MD, MS
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Related Content
Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Shengfeng Li
June 3rd 2024

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Ana C. Garrido-Castro, MD, a medical oncologist and codirector of the Triple-Negative Breast Cancer Working Group at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School
June 2nd 2024

Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer

Kevin Kalinsky, MD, MS, of Winship Cancer Institute
June 2nd 2024

Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression